Please use this identifier to cite or link to this item: http://ri.uaemex.mx/handle20.500.11799/109079
DC FieldValueLanguage
dc.creatorJosé Meneses Calderón-
dc.creatorHugo Mendieta Zerón-
dc.creatorSrivatsan Padmanabhan-
dc.date2020-06-
dc.date.accessioned2022-04-21T06:02:42Z-
dc.date.available2022-04-21T06:02:42Z-
dc.identifierhttp://hdl.handle.net/20.500.11799/109079-
dc.identifier.urihttp://ri.uaemex.mx/handle20.500.11799/109079-
dc.descriptionObjectives: To determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in reducing the need for invasive mechanical ventilatory support for patients with COVID-19. Hydroxychloroquine is currently being used in multiple trials with varying doses in an attempt to treat COVID-19. Nitazoxanide has powerful antiviral effects and proven efficacy against a range of viruses including SARS and MERS. Dual therapy by combining appropriate doses of these two medications with diverse activities against COVID-19 is expected to be better than monotherapy with hydroxychloroquine. Trial design: This is a single centre, randomized, controlled, single blinded, 2 arm (ratio 1:1) parallel group trial.-
dc.languageeng-
dc.publisherTrials-
dc.relation21-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0-
dc.source1745-6215-
dc.subjectHydroxychloroquine-
dc.subjectNitazoxanide-
dc.subjectCOVID-19-
dc.subjectRisk factors-
dc.subjectinfo:eu-repo/classification/cti/3-
dc.titleTreatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial.-
dc.typearticle-
dc.audiencestudents-
dc.audienceresearchers-
item.grantfulltextnone-
item.fulltextNo Fulltext-
Appears in Collections:Producción
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.